Skip to content
Explicyte Oncology CRO logo
  • Discovery

    FFPE target discovery

    Custom biospecimen sourcing

    Target identification & ranking

    Target expression profiling

    Data generation

    AI-ready Spatial Biology Datasets

    Explicyte 10x Genomics certified service provider

    Across Visium, Xenium, Chromium

    Explore 10x services →

    Emerging IO Targets: pipeline overview

    Browse database →
  • Preclinical

    Functional efficacy and MoA

    Tumor killing assays

    ADCC · T-cell · Antigen-specific

    Immune function & modulation

    Activation · Migration · MLR · Macrophage Polarization · Germinal Center Reaction

    Safety

    Cytokine release

    Additional capabilities

    Patient-Derived 3D tumor models

    Immune-native organoids · Tumor fragments

    Modality-specific assays

    ADCs · Multispecifics & engagers

    Xenium for cells

  • Trials

    Biomarker analysis

    Transcriptomic biomarkers

    Spatial transcriptomics · scRNAseq

    ISO-certified pathology services

    IHC/IF assay development · Assay validation · TLS scoring

    Peripheral biomarkers

    Proteomics · Flow cytometry · scRNAseq

    Explicyte is ISO 9001 and ISO 13485 certified for biomarker and immuno-oncology services

    Certified IHC/IF biomarker services

    Clinical-grade quality management

    Our tissue biomarker services →

    Explicyte 10x Genomics certified service provider

    10x Genomics-Certified Services

    Chromium X, Visium HD, Xenium

    Explore 10x-certified services →

  • Resources

    Publications

    Case studies

    Posters & abstracts

    IO Target Database

    Events & webinars

    News & press

  • About

    Company

    Commitments

    Careers

MultiOmics
Contact us

Resources / Cure51 – A unique Xenium dataset of cancer outliers

← Back to resources

Sponsor story

Cure51 – A unique Xenium dataset of cancer outliers

Cure51 – A unique Xenium dataset of cancer outliers
GastrointestinalAI DatasetsDiscoveryTarget discoveryFFPE tissueVisium HDXenium
Nicolas Wolikow CEO Cure51
Nicolas Wolikow
Co-founder & CEO·Cure 51

Nicolas Wolikow is the founder and CEO of Cure51, building the first worldwide database of exceptional cancer survivors. He brings over twenty years of leadership across healthcare, technology, and communications, with prior roles including Chief Digital Officer at Ipsen and co-founder of Qare. He holds degrees from HEC Paris, Sciences Po, and MGIMO Moscow.

Cure51 logo
Who we are

At Cure51, we study a rare and fascinating question: why do some patients survive the most aggressive cancers, far beyond all expectations?

Our Rosalind study focuses on metastatic pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers, and specifically on the exceptional survivors within this population.

Our challenge

To understand what sets PDAC survivors apart biologically, we needed to go deep: Xenium 5K spatial transcriptomics on 100+ FFPE samples, capturing gene expression directly within tissue architecture.

These samples are rare. Irreplaceable. And central to everything we’re building. That’s why choosing the right partner mattered enormously and why we turned to Explicyte.

What Explicyte did

Over six months of close collaboration, their team handled sample qualification, FFPE preparation, and full Xenium 5K execution with the rigor these samples deserved.

Weekly touchpoints, clean reporting, and sharp technical input at every critical step kept the project on track from start to finish.

The outcome

The result? High-quality data, delivered on time and we’re already putting it to work.

We are now actively exploring this unique spatial dataset and have identified new targets of interest in PDAC. This is exactly the kind of insight that can open new paths for patients who currently have very few options.

A big thank you to the Explicyte team for their expertise and partnership throughout this study. This is the kind of collaboration that turns ambitious science into tangible progress. 🙏

Could your program use this approach?

Start a conversation
← Back to resources

Explicyte Oncology CRO logo

The precision oncology CRO

229 cours de l’Argonne
33000 Bordeaux, France

Subscribe to our newsletter

By subscribing, you agree to receive Explicyte’s email updates, tailored to your interests based on the emails you open and the links you click. You can unsubscribe at any time. Privacy policy

Explicyte

  • About us
  • Commitments
  • News & Press
  • Careers
  • Contact

Discovery

  • FFPE tissues
  • Target identification
  • Target expression
  • Spatial biology for AI
  • 10x CSP services

Preclinical

  • Tumor killing
  • Immuno-modulation
  • Cytokine release
  • Patient-derived 3D models
  • ADC, Multispecifics

Trials

  • Transcriptomics
  • Peripheral markers
  • ISO-certified pathology
  • TLS detection

Multiomics

  • Atera
  • Xenium
  • Visium HD
  • scRNAseq
  • Digital pathology
  • Bioinformatics

Resources

  • Publications
  • Posters
  • Events & webinars
  • Case studies
  • IO targets database

© 2026 Explicyte. All rights reserved.

© 2026 Explicyte. All rights reserved.

    • Privacy policy
    • Terms of Use
    • Terms of service

 

Linkedin Youtube
Explicyte

Oncology CRO

Also at Explicyte Multi-Omics services Spatial Biology, scRNA-seq, Proteomics, Flow Cytometry, Bioinformatics 10x Genomics Certified Service Provider

Discovery

Overview
  • Custom biospecimen sourcing
  • Target identification & ranking
  • Target expression profiling
  • AI-Ready spatial biology datasets
10x Genomics Certified Service Provider

Preclinical

Overview
  • Patient-derived 3D tumor models
  • Xenium STAMP single-cell profiling

Tumor killing assays

Overview
  • ADCC
  • T-cell killing
  • Antigen-specific killing

Immune modulation assays

Overview
  • Immune cell activation
  • Cell Migration
  • Mixed lymphocyte reaction
  • Macrophage polarization
  • Germinal center reaction
  • Cytokine release

Modality-specific assays

Overview
  • Multispecifics & engagers
  • Antibody-drug conjugates (ADC)

Trials

Overview
  • Peripheral biomarker analysis
  • Transcriptomic biomarkers
  • ISO-certified pathology services
  • Multiplex IF panel for TLS scoring
10x Genomics Certified Service Provider
Certified IHC/IF tissue biomarker services ISO 9001 and ISO 13485 certified

Resources

Overview
  • Publications
  • Case studies
  • Posters & scientific abstracts
  • IO targets database
  • Events & webinars
  • News & press

About

Overview
  • Company
  • Commitments
  • Careers
Contact us